Update in Interstitial Lung Disease 2020.
作者信息
Podolanczuk Anna J, Wong Alyson W, Saito Shigeki, Lasky Joseph A, Ryerson Christopher J, Eickelberg Oliver
机构信息
Division of Pulmonary and Critical Care, Department of Medicine, Weill Cornell Medical College, Cornell University, New York, New York.
Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
出版信息
Am J Respir Crit Care Med. 2021 Jun 1;203(11):1343-1352. doi: 10.1164/rccm.202103-0559UP.
Abstract
摘要
相似文献
1
Update in Interstitial Lung Disease 2020.2020年间质性肺疾病进展
Am J Respir Crit Care Med. 2021 Jun 1;203(11):1343-1352. doi: 10.1164/rccm.202103-0559UP.
2
Update in Interstitial Lung Disease 2019.2019年间质性肺疾病的进展
Am J Respir Crit Care Med. 2020 Aug 15;202(4):500-507. doi: 10.1164/rccm.202002-0360UP.
3
Update in diffuse parenchymal lung disease 2006.2006年弥漫性实质性肺疾病的进展
Am J Respir Crit Care Med. 2007 Apr 1;175(7):655-60. doi: 10.1164/rccm.200701-052UP.
4
[Clinical problems and strategies of interstitial lung diseases].
Zhonghua Jie He He Hu Xi Za Zhi. 1999 Jan;22(1):6-7.
5
Respiratory bronchiolitis associated with interstitial lung disease and desquamative interstitial pneumonia.呼吸性细支气管炎伴间质性肺疾病和脱屑性间质性肺炎。
Clin Chest Med. 2004 Dec;25(4):717-26, vi. doi: 10.1016/j.ccm.2004.06.004.
6
[Smoking and interstitial lung disease? Commentary to the article of E. Wiatr "smoking-related interstitial lung diseases"].[吸烟与间质性肺疾病？对E. 维亚特《吸烟相关的间质性肺疾病》一文的评论]
Pneumonol Alergol Pol. 2009;77(3):341-3; author reply 344.
7
[Interstitial lung diseases. A turning point in diagnosis and treatment].[间质性肺疾病。诊断与治疗的转折点]
Rev Prat. 2014 Sep;64(7):915-6.
8
When and how should the patients with dermatomyositis be assessed for interstitial lung disease?
Chin Med J (Engl). 2010 Mar 5;123(5):515-6.
9
[Interstitial lung diseases].[间质性肺疾病]
Internist (Berl). 2000 May;41(5):467-79. doi: 10.1007/s001080050540.
10
Interstitial lung disease - An approach to diagnosis and management.间质性肺疾病——诊断与管理方法
Aust Fam Physician. 2010 Mar;39(3):106-10.
引用本文的文献
1
Homocysteine and risk of interstitial lung disease: A mendelian randomization approach to causal inference.同型半胱氨酸与间质性肺疾病风险：因果推断的孟德尔随机化方法
Sarcoidosis Vasc Diffuse Lung Dis. 2025 Jun 25;42(2):16386. doi: 10.36141/svdld.v42i2.16386.
2
Advanced interstitial lung disease: Evidence-based management and clinical approach.晚期间质性肺疾病：基于证据的管理与临床方法。
Sarcoidosis Vasc Diffuse Lung Dis. 2025 Jun 25;42(2):16206. doi: 10.36141/svdld.v42i2.16206.
3
Secreted Phosphoprotein 1 in Lung Diseases.肺部疾病中的分泌型磷蛋白1
Metabolites. 2025 May 30;15(6):365. doi: 10.3390/metabo15060365.
4
Predictive role of inflammatory markers in characterizing the progression of interstitial lung disease: a retrospective analysis.炎症标志物在间质性肺疾病进展特征中的预测作用：一项回顾性分析
Am J Transl Res. 2025 May 15;17(5):3485-3495. doi: 10.62347/JZTW5621. eCollection 2025.
5
Inequalities and age-period-cohort effects of global and regional burden for interstitial lung disease and pulmonary sarcoidosis: based on Global Burden of Disease study 2021.间质性肺疾病和结节病的全球及区域负担的不平等与年龄-时期-队列效应：基于《2021年全球疾病负担研究》
Front Med (Lausanne). 2025 May 26;12:1471402. doi: 10.3389/fmed.2025.1471402. eCollection 2025.
6
Real-world care patterns and specialist encounters of patients with systemic autoimmune rheumatic disease-related interstitial lung disease in the United States: a retrospective administrative claims database analysis.美国系统性自身免疫性风湿疾病相关间质性肺疾病患者的真实世界护理模式和专科诊疗情况：一项回顾性行政索赔数据库分析
Rheumatology (Oxford). 2025 Apr 23. doi: 10.1093/rheumatology/keaf200.
7
Advances in idiopathic pulmonary fibrosis diagnosis and treatment.特发性肺纤维化诊断与治疗的进展
Chin Med J Pulm Crit Care Med. 2025 Mar 7;3(1):12-21. doi: 10.1016/j.pccm.2025.02.001. eCollection 2025 Mar.
8
Efficacy and safety of antifibrotic drugs for interstitial lung diseases other than IPF: A systematic review, meta-analysis and trial sequential analysis.抗纤维化药物治疗除特发性肺纤维化外的间质性肺疾病的疗效和安全性：一项系统评价、荟萃分析和试验序贯分析
PLoS One. 2025 Feb 7;20(2):e0318877. doi: 10.1371/journal.pone.0318877. eCollection 2025.
9
CTHRC1: An Emerging Hallmark of Pathogenic Fibroblasts in Lung Fibrosis.CTHRC1：肺纤维化中病理性成纤维细胞的新兴标志。
Cells. 2024 May 30;13(11):946. doi: 10.3390/cells13110946.
10
Causal relationship between serum metabolites and interstitial lung disease in humans: A mendelian randomization study.血清代谢物与人类间质性肺病的因果关系：一项孟德尔随机化研究。
Technol Health Care. 2024;32(5):3485-3496. doi: 10.3233/THC-240285.
本文引用的文献
1
Effect of Co-trimoxazole (Trimethoprim-Sulfamethoxazole) vs Placebo on Death, Lung Transplant, or Hospital Admission in Patients With Moderate and Severe Idiopathic Pulmonary Fibrosis: The EME-TIPAC Randomized Clinical Trial.复方新诺明（甲氧苄啶-磺胺甲噁唑）与安慰剂对中重度特发性肺纤维化患者死亡、肺移植或住院的影响：EME-TIPAC 随机临床试验。
JAMA. 2020 Dec 8;324(22):2282-2291. doi: 10.1001/jama.2020.22960.
2
Exposure Assessment Tools for Hypersensitivity Pneumonitis. An Official American Thoracic Society Workshop Report.过敏性肺炎的暴露评估工具。美国胸科学会官方研讨会报告。
Ann Am Thorac Soc. 2020 Dec;17(12):1501-1509. doi: 10.1513/AnnalsATS.202008-942ST.
3
Registries for Idiopathic Pulmonary Fibrosis: When Is It Time to Go Global?特发性肺纤维化登记处：何时走向全球？
Ann Am Thorac Soc. 2020 Nov;17(11):1378-1379. doi: 10.1513/AnnalsATS.202007-835ED.
4
Making Sense of Bronchoalveolar Lavage Lymphocytosis in Fibrotic Interstitial Lung Disease.
Ann Am Thorac Soc. 2020 Nov;17(11):1382-1383. doi: 10.1513/AnnalsATS.202007-818ED.
5
Lung Iron Overload Does Not Exacerbate the Fibrotic Response to Bleomycin in a Mouse Model of Pulmonary Fibrosis.
Am J Respir Cell Mol Biol. 2020 Nov;63(5):713-716. doi: 10.1165/rcmb.2020-0192LE.
6
A FOX-like Mechanism Regulating Lung Fibroblasts: Are We Getting There?一种调节肺成纤维细胞的类FOX机制：我们正在接近目标吗？
Am J Respir Cell Mol Biol. 2020 Dec;63(6):723-724. doi: 10.1165/rcmb.2020-0441ED.
7
Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study.间质性肺疾病患者 COVID-19 住院治疗结局。一项国际多中心研究。
Am J Respir Crit Care Med. 2020 Dec 15;202(12):1656-1665. doi: 10.1164/rccm.202007-2794OC.
8
Senescence of Alveolar Type 2 Cells Drives Progressive Pulmonary Fibrosis.肺泡 II 型细胞衰老导致进行性肺纤维化。
Am J Respir Crit Care Med. 2021 Mar 15;203(6):707-717. doi: 10.1164/rccm.202004-1274OC.
9
Stiffness of the Extracellular Matrix: A Regulator of Prostaglandins in Pulmonary Fibrosis?细胞外基质的硬度：肺纤维化中前列腺素的调节因子？
Am J Respir Cell Mol Biol. 2020 Dec;63(6):721-722. doi: 10.1165/rcmb.2020-0398ED.
10
FOXL1 Regulates Lung Fibroblast Function via Multiple Mechanisms.FOXL1 通过多种机制调节肺成纤维细胞功能。
Am J Respir Cell Mol Biol. 2020 Dec;63(6):831-842. doi: 10.1165/rcmb.2019-0396OC.
Zotero 插件